Company / R&D Expense
Viatris R&D Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$965.9M
FY2025
5-year range
$512.6M / $965.9M
FY2021-FY2025
Trend
+19.4%
vs FY2024
Sector context
#19 of 210
Health Care
What the data says
Among 210 Health Care companies, Viatris is in the top 9% for r&d expense. R&D Expense has increased for 3 consecutive years, from $513M in FY2022 to $966M in FY2025.
Based on SEC 10-K filings.
$966M in FY2025 with a 5-year CAGR of +6.5%. Top quartile in the Health Care sector.
Improved from $805M to $966M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +23.5%
- 5-Year CAGR
- +6.5%
- 10-Year CAGR
- -
Sector benchmark
Top 9% in Health CareTop 9% of 210This company $965.9M Sector average $644.1M
▼
+50.0% above sector average
Key checks
Key Insights
- Viatris's r&d expense has grown for 3 consecutive years.
- 5-year CAGR of +6.5%, indicating consistent growth.
- In FY2025, r&d expense increased 19.4% year-over-year.
- Ranks #19 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $965.9M | +19.4% |
| FY2024 | $808.7M | +0.4% |
| FY2023 | $805.2M | +57.1% |
| FY2022 | $512.6M | -19.9% |
| FY2021 | $639.9M | -9.2% |
| FY2020 | $704.5M | +10.1% |
| FY2019 | $639.9M | -9.2% |
| FY2018 | $704.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026